Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Study 9 for newly diagnosed childhood acute lymphoblastic leukemia
ACTRN12611001233910Phase 3Completed
- Sponsor
- Australian Pharmaceutical Industries
- Start
- Dec 2011
- Modality
- Small Molecules, Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 7
01
Overview
A Phase 3 trial of pegaspargase, daunorubicin in acute lymphoblastic leukemia (ALL), sponsored by Australian Pharmaceutical Industries. Started Dec 2011; status: completed.
02
Drugs
pegaspargasedaunorubicin
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on ACTRN12611001233910.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12611001233910.